SCHEMBL423732

SCHEMBL423732

CN1C(=O)[N]C(=O)C1(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14907286 0.67 CNR1 (0.33)
SCHEMBL4147170 0.63 HSD17B10 (0.33)
SCHEMBL12341138 0.62
SCHEMBL4338332 0.58 LMNA (0.31)
SCHEMBL4348682 0.57
SCHEMBL6579528 0.56 ATAD2 (0.33)
SCHEMBL8902159 0.55 ALDH1A1 (0.36)
SCHEMBL18179804 0.55 ADRA2C (0.35)
SCHEMBL417571 0.54 PLA2G7 (0.39)
SCHEMBL15960838 0.54 LMNA (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4750272-B2 2011-08-17 JP claimed
JP-4238334-B2 2009-03-18 JP claimed
EP-1918278-A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases Novartis AG (CH) 2008-05-07 EP claimed
US-7358265-B2 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors VERNALIS (R&D) LTD 2008-04-15 US claimed
EP-1476438-B1 OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS VERNALIS R&D LTD (GB) 2007-04-18 EP claimed
US-20050222189-A1 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors VERNALIS (OXFORD) LTD (GB) 2005-10-06 US claimed
WO-2004101537-A1 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LTD (GB) 2004-11-25 WO claimed
EP-1476438-A1 OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS Vernalis (Oxford) Ltd (GB) 2004-11-17 EP claimed
US-6790834-B1 Cytostatic agents BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) 2004-09-14 US claimed
US-6624196-B2 Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders WARNER-LAMBERT COMPANY 2003-09-23 US claimed
WO-1998023588-A1 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1998-06-04 WO claimed
WO-1998011063-A1 CYTOSTATIC HYDROXAMIC ACID DERIVATIVES BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1998-03-19 WO claimed
WO-1997003783-A9 METALLOPROTEINASE INHIBITORS 1997-04-03 WO claimed
EP-0763013-A1 HYDROXYLAMINE DERIVATIVES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS F. HOFFMANN-LA ROCHE AG (CH) 1997-03-19 EP claimed
WO-1997003783-A1 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1997-02-06 WO claimed
WO-1995033709-A1 HYDROXYLAMINE DERIVATIVES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS F. HOFFMANN-LA ROCHE AG (CH) 1995-12-14 WO claimed
EP-0684240-A1 Hydroxamic acid derivatives with tricyclic substitution F. HOFFMANN-LA ROCHE AG (CH) 1995-11-29 EP claimed
US-5447929-A Collagenase inhibitors for degenerative joint disease, antitumor agents or atherosclerosis HOFFMANN-LA ROCHE INC. (US) 1995-09-05 US claimed
US-5318964-A Collangenase inhibitors; antiarthritic and -tumor agents; rheumatic diseases; osteoarthritis; atherosclerosis; multiple sclerosis HOFFMANN-LA ROCHE INC. (US) 1994-06-07 US claimed
EP-0574758-A1 Hydroxamic acid derivatives as collagenase inhibitors F. HOFFMANN-LA ROCHE AG (CH) 1993-12-22 EP claimed